<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Genetic forms of hypoparathyroidism</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Genetic forms of hypoparathyroidism</h1>
<div class="graphic"><div class="figure"><div class="ttl">Genetic forms of hypoparathyroidism</div><div class="cntnt"><table cellspacing="0"><colgroup width="30%"></colgroup><colgroup span="4" width="10%"></colgroup><colgroup width="30%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">Inheritance</td> <td class="subtitle1">Chromosomal locus</td> <td class="subtitle1">Cytogenetic/genetic alteration</td> <td class="subtitle1">OMIM phenotype number (#)</td> <td class="subtitle1">Clinical findings associated with chronic hypoparathyroidism</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Disorders of parathyroid gland formation</td> </tr> <tr> <td class="indent1">DiGeorge syndrome type 1 (DGS1)</td> <td>AD</td> <td>22q11.21</td> <td>del. (<em>TBX1</em>)</td> <td><a href="https://www.omim.org/entry/188400" target="_blank">188400</a></td> <td rowspan="2">Thymic hypoplasia with immune deficiency, conotruncal heart malformations, cleft palate, dysmorphic facies, short stature, developmental delay, gastrointestinal issues, thrombocytopenia, cognitive impairment, psychiatric disorders</td> </tr> <tr> <td class="indent1">DiGeorge syndrome type 2 (DGS2)</td> <td>AD</td> <td>10p14-p13</td> <td>del. (<em>NEBL</em>)</td> <td><a href="https://www.omim.org/entry/601362" target="_blank">601362</a></td> </tr> <tr> <td class="indent1">CHARGE syndrome</td> <td>AD</td> <td>8q12.2</td> <td><em>CHD7</em></td> <td><a href="https://www.omim.org/entry/214800" target="_blank">214800</a></td> <td>Choanal atresia and malformations of the heart, inner ear (deafness), and retina (coloboma), poor growth, genital hypoplasia</td> </tr> <tr> <td class="indent1">Hypoparathyroidism, sensorineural deafness and renal dysplasia (HDR)</td> <td>AD</td> <td>10p14</td> <td><em>GATA3</em></td> <td><a href="https://www.omim.org/entry/146255" target="_blank">146255</a></td> <td>Deafness, renal dysplasia</td> </tr> <tr> <td class="indent1">Sanjad-Sakati syndrome</td> <td>AR</td> <td>1q42.3</td> <td><em>TBCE</em></td> <td><a href="https://www.omim.org/entry/241410" target="_blank">241410</a></td> <td>Growth attenuation, dysmorphic facial features, developmental delay</td> </tr> <tr> <td class="indent1">Kenny-Caffey syndrome type 1 (KCS1)</td> <td>AR</td> <td>1q42.3</td> <td><em>TBCE</em></td> <td><a href="https://www.omim.org/entry/244460" target="_blank">244460</a></td> <td rowspan="2">Severe proportionate short stature, cortical thickening with medullary stenosis of the tubular bones, craniofacial abnormalities, eye abnormalities</td> </tr> <tr> <td class="indent1">Kenny-Caffey syndrome type 2 (KCS2)</td> <td>AD</td> <td>11q12.1</td> <td><em>FAM111A</em></td> <td><a href="https://www.omim.org/entry/127000" target="_blank">127000</a></td> </tr> <tr> <td class="indent1">Gracile bone dysplasia (GCLEB)</td> <td>AD</td> <td>11q12.1</td> <td><em>FAM111A</em></td> <td><a href="https://www.omim.org/entry/602361" target="_blank">602361</a></td> <td>Gracile bones with thin diaphyses, premature closure of basal cranial sutures, and microphthalmia</td> </tr> <tr> <td class="indent1">Kearns-Sayre syndrome (KSS)</td> <td>–</td> <td>–</td> <td>Mitochondrial DNA</td> <td><a href="https://www.omim.org/entry/530000" target="_blank">530000</a></td> <td>Ophthalmoplegia, pigmentary degeneration of the retina, and cardiomyopathy</td> </tr> <tr> <td class="indent1">Pearson marrow-pancreas syndrome</td> <td>–</td> <td>–</td> <td>Mitochondrial DNA</td> <td><a href="https://www.omim.org/entry/557000" target="_blank">557000</a></td> <td>Bone marrow failure (altered hematopoietic precursors), diabetes, malabsorption</td> </tr> <tr> <td class="indent1">Mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes syndrome (MELAS)</td> <td>–</td> <td>–</td> <td>Mitochondrial DNA</td> <td><a href="https://www.omim.org/entry/540000" target="_blank">540000</a></td> <td>Myopathy, encephalopathy, lactic acidosis, stroke-like episodes, seizures, cortical blindness, hemianopsia, episodic vomiting</td> </tr> <tr> <td class="indent1">Mitochondrial trifunctional protein deficiency syndrome (MTPD)</td> <td>AR</td> <td>2p23.3</td> <td><em>HADHA</em>, <em>HADHB</em></td> <td><a href="https://www.omim.org/entry/609015" target="_blank">609015</a></td> <td>Hypoglycemia, cardiomyopathy, myopathy with hypotonia, episodic vomiting, liver disease, peripheral neuropathy</td> </tr> <tr> <td class="indent1">Medium-chain acyl-CoA dehydrogenase deficiency (ACADMD)</td> <td>AR</td> <td>1p31.1</td> <td><em>ACADM</em></td> <td><a href="https://www.omim.org/entry/201450" target="_blank">201450</a></td> <td>Hypoglycemia, lethargy, vomiting, seizures</td> </tr> <tr> <td class="indent1">Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHAD)</td> <td>AR</td> <td>2p23.3</td> <td><em>HADHA</em></td> <td><a href="https://www.omim.org/entry/609016" target="_blank">609016</a></td> <td>Recurrent hypoglycemia, rapidly progressive myopathy, cardiomyopathy</td> </tr> <tr> <td class="indent1">Smith-Lemli-Opitz syndrome (SLOS)</td> <td>AR</td> <td>11q13.4</td> <td><em>DHCR7</em></td> <td><a href="https://www.omim.org/entry/270400" target="_blank">270400</a></td> <td>Multiple congenital malformations (microcephaly, atypical genital appearance and nostrils), intellectual disability, adrenal insufficiency</td> </tr> <tr> <td class="indent1">Familial isolated hypoparathyroidism type 2 (FIH2)</td> <td>AD, AR</td> <td>6p24.2</td> <td><em>GCM2</em></td> <td><a href="https://www.omim.org/entry/618883" target="_blank">618883</a></td> <td>–</td> </tr> <tr> <td class="indent1">Hypoparathyroidism X-linked recessive (HYPX)</td> <td>XLR</td> <td>Xq27.1</td> <td>del./ins. (<em>SOX3</em>)</td> <td><a href="https://www.omim.org/entry/307700" target="_blank">307700</a></td> <td>–</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Disorders of parathyroid hormone secretion</td> </tr> <tr> <td class="indent1">Autosomal dominant hypocalcemia with hypercalciuria type 1 (ADH1)/Bartter syndrome subtype 5</td> <td>AD</td> <td>3q13.3-q21.1</td> <td><em>CaSR</em></td> <td><a href="https://www.omim.org/entry/601198" target="_blank">601198</a></td> <td>Hypomagnesemia, hypercalciuria; possibly associated with Bartter syndrome</td> </tr> <tr> <td class="indent1">Autosomal dominant hypocalcemia with hypercalciuria type 2 (ADH2)</td> <td>AD</td> <td>19p13.3</td> <td><em>GNA11</em></td> <td><a href="https://www.omim.org/entry/615361" target="_blank">615361</a></td> <td>Hypomagnesemia, hypercalciuria</td> </tr> <tr> <td class="indent1">Familial isolated hypoparathyroidism type 1 (FIH)</td> <td>AD, AR</td> <td>11p15.3</td> <td><em>PTH</em></td> <td><a href="https://www.omim.org/entry/146200" target="_blank">146200</a></td> <td>–</td> </tr> <tr> <td class="indent1" colspan="6">Hypomagnesemia syndromes</td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>Hypomagnesemia 1, intestinal (HOMG1)</li> </ul> </td> <td>AR</td> <td>9q21.13</td> <td><em>TRPM6</em></td> <td><a href="https://www.omim.org/entry/602014" target="_blank">602014</a></td> <td>Hypercalciuria, nephrocalcinosis</td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>Hypomagnesemia 2, renal (HOMG2)</li> </ul> </td> <td>AD</td> <td>11q23.3</td> <td><em>FXYD2</em></td> <td><a href="https://www.omim.org/entry/154020" target="_blank">154020</a></td> <td>Hypocalciuria</td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>Hypomagnesemia 3, renal (HOMG3)</li> </ul> </td> <td>AR</td> <td>3q28</td> <td><em>CLDN16</em></td> <td><a href="https://www.omim.org/entry/248250" target="_blank">248250</a></td> <td>Progressive loss of kidney function, amelogenesis imperfecta</td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>Hypomagnesemia 4, renal (HOMG4)</li> </ul> </td> <td>AR</td> <td>4q25</td> <td><em>EGF</em></td> <td><a href="https://www.omim.org/entry/611718" target="_blank">611718</a></td> <td>Mild to moderate developmental delay; seizures</td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>Hypomagnesemia 5, renal (HOMG5)</li> </ul> </td> <td>AR</td> <td>1p34.2</td> <td><em>CLDN19</em></td> <td><a href="https://www.omim.org/entry/248190" target="_blank">248190</a></td> <td>Progressive kidney failure, nephrocalcinosis, and severe visual impairment, amelogenesis imperfecta</td> </tr> <tr> <td class="indent1"> <ul class="decimal_heading"> <li>Hypomagnesemia 6, renal (HOMG6)</li> </ul> </td> <td>AD</td> <td>10q24.32</td> <td><em>CNNM2</em></td> <td><a href="https://www.omim.org/entry/613882" target="_blank">613882</a></td> <td>–</td> </tr> <tr> <td class="indent1">Gitelman syndrome (GTLMNS)</td> <td>AR</td> <td>16q13</td> <td><em>SLC12A3</em></td> <td><a href="https://www.omim.org/entry/263800" target="_blank">263800</a></td> <td>Hypokalemic metabolic alkalosis, hypocalciuria, abdominal pains, chondrocalcinosis</td> </tr> <tr> <td class="indent1">Episodic ataxia type 1 (EA1)</td> <td>AD</td> <td>12p13.32</td> <td><em>KCNA1</em></td> <td><a href="https://www.omim.org/entry/160120" target="_blank">160120</a></td> <td>Spells of incoordination and imbalance, often associated with progressive ataxia</td> </tr> <tr> <td class="indent1">Hypomagnesemia, hypertension, and hypercholesterolemia syndrome</td> <td>–</td> <td>–</td> <td>Mitochondrial DNA</td> <td><a href="https://www.omim.org/entry/500005" target="_blank">500005</a></td> <td>Hypertension, hypercholesterolemia</td> </tr> <tr> <td class="indent1">Hypomagnesemia, seizures, and impaired intellectual development 1 (HOMGSMR1)</td> <td>AD, AR</td> <td>10q24.32</td> <td><em>CNNM2</em></td> <td><a href="https://www.omim.org/entry/616418" target="_blank">616418</a></td> <td>Seizures, delayed psychomotor development</td> </tr> <tr> <td class="indent1">Hypomagnesemia, seizures, and impaired intellectual development 2 (HOMGSMR2)</td> <td>AD</td> <td>1p13.1</td> <td><em>ATP1A1</em></td> <td><a href="https://www.omim.org/entry/618314" target="_blank">618314</a></td> <td>Significantly impaired intellectual development</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Damage to the parathyroid glands</td> </tr> <tr> <td class="indent1">Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome (APECED)</td> <td>AD, AR</td> <td>21q22.3</td> <td><em>AIRE</em></td> <td><a href="https://www.omim.org/entry/240300" target="_blank">240300</a></td> <td>Adrenal insufficiency, chronic mucocutaneous candidiasis, and other possible autoimmune diseases, eg, celiac disease, vitiligo, type 1 diabetes, hypogonadism</td> </tr> <tr> <td class="indent1">Other autoimmune polyendocrine syndromes</td> <td>–</td> <td>–</td> <td>(Polygenic, HLA-related)</td> <td>–</td> <td>Association of organ-specific autoimmune diseases</td> </tr> </tbody></table></div><div class="graphic_footnotes">OMIM: Online Mendelian Inheritance in Man; AD: autosomal dominant; AR: autosomal recessive; XLR: X-linked recessive; HLA: human leukocyte antigen.</div><div class="graphic_reference">From: Mannstadt M, Cianferotti L, Gafni RI, et al. Hypoparathyroidism: Genetics and diagnosis. J Bone Miner Res 2022; 37:2411. <a href="https://asbmr.onlinelibrary.wiley.com/doi/10.1002/jbmr.4667" target="_blank">https://asbmr.onlinelibrary.wiley.com/doi/10.1002/jbmr.4667</a>. Copyright © 2022 The Authors. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href="permissions@wiley.com"><span class="__cf_email__" data-cfemail="45352037282c36362c2a2b3605322c29203c6b262a28">[email protected]</span></a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href="https://onlinelibrary.wiley.com/" target="_blank">https://onlinelibrary.wiley.com/</a>).</div><div id="graphicVersion">Graphic 142074 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
